Abstracts tagged "Cardiovascular disease"

Abstract Number: 887 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez¹, Mª Angeles Aguirre², Nuria Barbarroja¹, Tomás Cerdó-Ráez³, Maria Laura Bertolaccini⁴, Munther A. Khamashta⁵, Antonio Rodriguez-Ariza⁶, Yolanda Almaden⁷, Husam Khraiwesh⁸, Jose Antonio Gonzalez-Reyes⁹, Jose Manuel Villalba¹⁰, Eduardo Collantes¹¹ and Mª Jose Cuadrado¹², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Imibic, Córdoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁷Imibic, Códoba, Spain, ⁸UCO, Córdoba, Spain, ⁹Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ¹⁰Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ¹¹Rheumatology, Hospital Reina Sofia, Cordoba, Spain, ¹²Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…
Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Birgul Ay¹, Dilek Keskin², Goksal Keskin³ and Ayhan Dinc⁴, ¹Internal Medicine, DYB Research and Training Hospital, Ankara, Turkey, ²Immunology, DYB Research and Training Hospital, Ankara, Turkey, ³Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, ⁴Rheumatology, Patio Clinic, Ankara, Turkey
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…
Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Hitomi Kobayashi^1,2, Isamu Yokoe³, Hiroshi Sato², Yasuyuki Kobayashi⁴, Kihei Yoneyama⁵, Masaharu Hirano⁶ and Masami Takei⁷, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Cardiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁶Cardiology, Tokyo Medical Colleage, Tokyo, Japan, ⁷Division of Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…
Abstract Number: 2828 • 2013 ACR/ARHP Annual Meeting
The Performance Of The Original and An Updated Cardiovascular Risk Algorithm (SCORE) In Patients With Rheumatoid Arthritis
Elke.E.A. Arts¹, Calin Popa¹, Alfons A. den Broeder², Anne Grete Semb³, Tracey Toms⁴, George Kitas⁴, Piet L.C.M. van Riel¹ and Jaap Fransen¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom
Background/Purpose: Cardiovascular (CV) risk in rheumatoid arthritis (RA) is increased. The CV risk algorithms for the general population may underestimate the risk of cardiovascular disease…
Abstract Number: 1709 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications
Christie M. Bartels¹, Sarah Tweddell², Barbara Bowers³, Elizabeth Jacobs⁴ and Tonya Roberts³, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW School of Medicine and Public Health, Madison, WI, ³UW School of Nursing, Madison, WI, ⁴Internal Medicine, UW School of Medicine and Public Health, Madison, WI
Background/Purpose: Although rheumatoid arthritis (RA) increases cardiovascular disease (CVD) risk, RA patients receive less CVD preventive care than peers. We previously showed gaps in lipid…
Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study
Lotta Ljung^1,2, Johan Askling³, Solbritt M. Rantapää-Dahlqvist⁴, Lennart T.H. Jacobsson⁵ and The ARTIS Study Group⁶, ¹Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…
Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
C. Charles-Schoeman¹, P Wicker², M. A. Gonzalez-Gay³, S. P. Wood⁴, M.G. Boy⁴, J. Geier⁵, D. Gruben⁴, K. Soma⁴ and R. Riese⁴, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²PW Consulting LLC, Mystic, CT, ³Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…
Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Michael Lucke¹, Soo Hyun Kim² and M. Elaine Husni³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…
Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting
Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Audrey SL Low¹, Kimme L. Hyrich², Mark Lunt³, Louise K. Mercer³, Christopher Gale^4,5, Kath Watson⁶, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium¹, William G. Dixon⁷, Deborah P. Symmons^3,8 and On behalf of the BSRBR⁹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, ⁵Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁷The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁹British Society for Rheumatology, London, United Kingdom
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…
Abstract Number: 1720 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout
Seoyoung C. Kim¹, Sebastian Schneeweiss², Niteesh Choudhry³, Jun Liu⁴, Robert J. Glynn³ and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of hypertension and cardiovascular disease (CVD) such as myocardial infarction (MI) and stroke. Xanthine oxidase…
Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting
Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis
Lotta Ljung^1,2, Lennart T.H. Jacobsson³, Solbritt M. Rantapää-Dahlqvist⁴, Johan Askling⁵ and The ARTIS Study Group⁶, ¹Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁴Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 303 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
Alexis Ogdie¹, Yiding Yu², Kevin Haynes³, Samantha Maliha⁴, Thorvardur Love^5,6, Andrea Troxel⁷, Sean Hennessy⁸, David Margolis⁹, Stephen Kimmel¹⁰, Nehal N. Mehta¹¹, Hyon Choi^12,13 and Joel Gelfand¹⁴, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Medicine, Brigham and Women's Hospital, Boston, MA, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁶Landspitali University Hospital, Reykjavik, Iceland, ⁷Biostatistics and Epidemiology, University of Pennsylvania., Philadelphia, PA, ⁸Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹⁰Cardiology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ¹¹National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD, ¹²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA
Risk of Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A general population-based cohort studyBackground/Purpose: Psoriatic arthritis (PsA), psoriasis, and rheumatoid arthritis…
Abstract Number: 2766 • 2013 ACR/ARHP Annual Meeting
Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis
Lesley-Anne Bissell¹, Elizabeth Hensor², Sarah L. Mackie², Agata Burska³, Jackie L. Nam², Lukasz Kozera², Helen I. Keen⁴, Edith Villeneuve², Heike Eberl⁵, Helena Donica⁶, Philip G. Conaghan⁷, Jacqueline Andrews², Paul Emery⁸ and Ann W. Morgan², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases, the University of Leeds, Leeds, AL, United Kingdom, ⁴Leeds, Leeds, United Kingdom, ⁵Roche Molecular Diagnostics, Burgess Hill, United Kingdom, ⁶Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, ⁷NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁸Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of…
Abstract Number: 1672 • 2013 ACR/ARHP Annual Meeting
Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort
Grégory Pugnet¹, Laurent Sailler², Guillaume Moulis³, Jean-Pascal Fournier⁴, Robert Bourrel⁵, Jean-Louis Montastruc⁶ and Maryse lapeyre-Mestre⁶, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Clinical Pharmacology Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ⁴Toulouse University, INSERM UMR 1027, Toulouse, France, ⁵Service Médical, Caisse Nationale de l'Assurance Maladie échelon régional, Midi-Pyrénées, Toulouse, France, ⁶Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: No population-based study has assessed serious cardiovascular events (sCVE) risk factors in Giant Cell Arteritis (GCA). The aim of our study was to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.